Zacks Research Predicts OPKO Health FY2028 Earnings

OPKO Health, Inc. (NASDAQ:OPK) – Zacks Research issued their FY2028 earnings per share estimates for OPKO Health in a research note issued to investors on Thursday, March 19th. Zacks Research analyst Team anticipates that the biotechnology company will post earnings per share of ($0.16) for the year. The consensus estimate for OPKO Health’s current full-year earnings is ($0.25) per share.

Several other research firms have also issued reports on OPK. Wall Street Zen lowered shares of OPKO Health from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of OPKO Health in a report on Thursday, January 22nd. Finally, Barrington Research lowered their price objective on OPKO Health from $2.25 to $1.50 and set an “outperform” rating for the company in a research report on Monday, March 2nd. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $2.03.

OPKO Health Stock Down 4.3%

NASDAQ:OPK opened at $1.12 on Friday. The company’s 50-day simple moving average is $1.23 and its 200-day simple moving average is $1.34. The company has a debt-to-equity ratio of 0.26, a quick ratio of 3.52 and a current ratio of 3.97. OPKO Health has a fifty-two week low of $1.10 and a fifty-two week high of $1.83. The stock has a market capitalization of $850.16 million, a P/E ratio of -3.73 and a beta of 1.50.

OPKO Health (NASDAQ:OPK) last announced its earnings results on Thursday, February 26th. The biotechnology company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.03. The business had revenue of $148.50 million during the quarter, compared to the consensus estimate of $139.76 million. OPKO Health had a negative net margin of 37.19% and a negative return on equity of 17.42%. The firm’s revenue was down 19.1% on a year-over-year basis. During the same period in the previous year, the company posted $0.01 earnings per share.

Institutional Investors Weigh In On OPKO Health

Institutional investors and hedge funds have recently made changes to their positions in the stock. Geode Capital Management LLC raised its stake in OPKO Health by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 11,061,318 shares of the biotechnology company’s stock worth $13,940,000 after acquiring an additional 67,973 shares during the last quarter. Millennium Management LLC increased its holdings in shares of OPKO Health by 39.2% in the first quarter. Millennium Management LLC now owns 6,386,911 shares of the biotechnology company’s stock valued at $10,602,000 after purchasing an additional 1,798,385 shares during the period. Goldman Sachs Group Inc. increased its holdings in shares of OPKO Health by 150.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 5,986,913 shares of the biotechnology company’s stock valued at $7,544,000 after purchasing an additional 3,600,378 shares during the period. UBS Group AG raised its stake in shares of OPKO Health by 12.1% in the fourth quarter. UBS Group AG now owns 5,352,784 shares of the biotechnology company’s stock worth $6,745,000 after purchasing an additional 577,248 shares during the last quarter. Finally, AWM Investment Company Inc. raised its stake in shares of OPKO Health by 8.1% in the second quarter. AWM Investment Company Inc. now owns 2,000,000 shares of the biotechnology company’s stock worth $2,640,000 after purchasing an additional 150,000 shares during the last quarter. 64.63% of the stock is currently owned by institutional investors and hedge funds.

More OPKO Health News

Here are the key news stories impacting OPKO Health this week:

• Positive Sentiment: Director John A. Paganelli purchased 10,000 shares at about $1.14, increasing his stake to 394,340 shares; insider buying can signal management confidence and offer short‑term support. SEC Filing
• Positive Sentiment: Barrington Research kept an Outperform/Buy stance on OPK, which may sustain interest from growth and penny‑stock investors despite other negative headlines. Barrington Article
• Neutral Sentiment: Zacks published thematic commentary noting OPKO’s strengths (RAYALDEE sales, partnerships) but flagged revenue declines and concentration risk — useful context for longer‑term holders evaluating risk/reward. Zacks Hold Article
• Negative Sentiment: Zacks Research sharply cut near‑term EPS estimates across multiple quarters and fiscal years (many quarterly EPS moved to roughly $(0.07)–$(0.08); FY2026/FY2027 lowered to about $(0.29)), signaling weaker expected profitability and raising the bar for operational improvements — a key reason for downward pressure on the stock today.
• Negative Sentiment: Barrington trimmed its price target from $2.25 to $1.50; although the firm left a Buy rating, the lower target reduces measured upside and can weigh on short‑term trader sentiment. InsiderMonkey Article

OPKO Health Company Profile

OPKO Health, Inc (NASDAQ:OPK) is a diversified, global healthcare company headquartered in Miami, Florida, with a focus on diagnostics, pharmaceuticals and biologics development. The company operates two main business segments—Laboratory Services and Pharma Services & Products—driven by its mission to advance patient care through innovation in testing and targeted therapies.

In its Laboratory Services segment, OPKO leverages BioReference Laboratories, one of the largest full-service commercial labs in the United States.